Chen JW, Gall MA, Yokoyama H, Jensen JS, Deckert M, Parving HH (1996). Raised serum sialic acid concentration in NIDDM patients with and without diabetic nephropathy. Diabetes Care 19(2):130-134.
Crossref

Cohen JD, Grimm RH, Smith WM (1981). Multiple risk factor intervention trial (MRFIT): VI. Intervention on blood pressure. Prev. Med. 10(4):501-518.
Crossref

Crook M (1993). The determination of plasma or serum sialic acid. Clin. Biochem. 26(1):31-38.
Crossref

Crook MA, Pickup JC, Lumb PJ, Georgino F, Webb DJ, Fuller JH (2001). Relationship between plasma sialic acid concentration and microvascular and macrovascular complications in type 1 diabetes. Diabetes Care 24(2):316-322.
Crossref

Gavella M, Lipovac V, Car A, Vučić M, Sokolić L, Rakoš R (2003). Serum sialic acid in subjects with impaired glucose tolerance and in newly diagnosed type 2 diabetic patients. Acta Diabetol. 40(2):95-100.

Ghosh J, Datta S, Pal M (2016). Role of sialic acid in prediction of diabetic nephropathy. Al Ameen J. Med. Sci. 9(1):58-64.

Guyton C, Hall JE (2016). Text Book of Medical Physiology. 13th Ed. Elsevier.

Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, Hoshino T, John WG, Kobold U, Little R, Mosca A (2004). IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin. Chem. 50(1):166-174.
Crossref

Jeremy WT (2003). Treating hypertension in diabetic nephropathy. Diabetes Care 26:180-205.

Katia LR, Abreu AAM, Marquez CG, Stanescu RL, Martin MIM, Fernandez EP (2015). Diabetic Nephropathy without Diabetes. J. Clin. Med. 4(7):1403-1427.
Crossref

Lindberg G, Eklund GA, Gullberg B, Råstam L (1991). Serum sialic acid concentration and cardiovascular mortality. BMJ 302(6769):143-146.
Crossref

Mahboob SMST (2008). Electrolytes and Na-K-ATPase: potential risk factors for the development of diabetic nephropathy. Pak. J. Pharm. Sci. 21(2):172-179.

Mehta SR, Kashyap AS, Das S (2009). Diabetes mellitus in India: The modern scourge. Med. J. Armed Forces India 65(1):50-54.
Crossref

Nayak BS, Bhakhta G (2005). Relationship between Sialic acid and metabolic variables in Indian type 2 diabetic patients. Lipid Health Dis. 4(1):15
Crossref

Pickup JC, Mattock MB, Chusney GD, Burt D (1997). NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40(11):1286-1292.
Crossref

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001). C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286(3):327-334.
Crossref

Salhanick AI, Amatruda JM (1988). Role of sialic acid in insulin action and the insulin resistance of diabetes mellitus. Am. J. Physiol. Endocrinol. Metab. 255(2):E173-E179.
Crossref

Shahid SM, Mahboob T (2006). Clinical correlation between frequent risk factors of diabetic nephropathy and serum sialic acid. Int. J. Diabetes Metab. 14:138-144.

Svennerholm L (1957). Quantitive estimation of sialic acids: II. A colorimetric resorcinol-hydrochloric acid method. Biochim. Biophys. Acta 24:604-611.
Crossref

WHO-World Health Organization (1985). Diabetes Mellitus, Report of a WHO study group, Geneva, Switzerland: World Health Organization.

Yarema K (2006). The sialic acid pathway in human cells. Baltimore: John Hopkins University, pp. 149-152.